- Home
- HUDI vs CVKD Comparison
HUDI vs CVKD Comparison
Compare HUDI & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUDI
- CVKD
- Stock Information
- Founded
- HUDI 1998
- CVKD 2022
- Country
- HUDI China
- CVKD United States
- Employees
- HUDI N/A
- CVKD N/A
- Industry
- HUDI Steel/Iron Ore
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- HUDI Industrials
- CVKD Health Care
- Exchange
- HUDI Nasdaq
- CVKD Nasdaq
- Market Cap
- HUDI 23.2M
- CVKD 20.8M
- IPO Year
- HUDI 2021
- CVKD 2023
- Fundamental
- Price
- HUDI $1.63
- CVKD $16.17
- Analyst Decision
- HUDI
- CVKD Strong Buy
- Analyst Count
- HUDI 0
- CVKD 2
- Target Price
- HUDI N/A
- CVKD $46.00
- AVG Volume (30 Days)
- HUDI 17.3K
- CVKD 79.1K
- Earning Date
- HUDI 02-03-2025
- CVKD 11-07-2024
- Dividend Yield
- HUDI N/A
- CVKD N/A
- EPS Growth
- HUDI N/A
- CVKD N/A
- EPS
- HUDI 0.18
- CVKD N/A
- Revenue
- HUDI $83,462,634.00
- CVKD N/A
- Revenue This Year
- HUDI N/A
- CVKD N/A
- Revenue Next Year
- HUDI N/A
- CVKD N/A
- P/E Ratio
- HUDI $8.84
- CVKD N/A
- Revenue Growth
- HUDI 7.65
- CVKD N/A
- 52 Week Low
- HUDI $1.55
- CVKD $5.40
- 52 Week High
- HUDI $4.25
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- HUDI 28.94
- CVKD 61.78
- Support Level
- HUDI $1.59
- CVKD $10.65
- Resistance Level
- HUDI $1.72
- CVKD $12.25
- Average True Range (ATR)
- HUDI 0.10
- CVKD 1.68
- MACD
- HUDI -0.02
- CVKD 0.32
- Stochastic Oscillator
- HUDI 14.68
- CVKD 76.54
About HUDI Huadi International Group Co. Ltd.
Huadi International Group Co Ltd is a manufacturer of industrial stainless steel seamless pipes and tubes products. Its products are used in the oil & gas transmission, chemistry engineering, food processing, medical devices, aeronautics and astronautics, boiler, irrigation works construction, automobile and naval architecture, paper mill and mechanical industries. Products are exported to the United States, Mexico, Thailand, Australia, Argentina, Taiwan, India, the Philippines, UAE and Canada. Geographically, majority revenue is generated from China.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.